Scientific Publications

Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity. Hess J, Ruf P, Lindhofer H. Future Oncol. 2012 Jan;8(1):73-85 See abstract

Trifunctional antibodies induce efficient antitumour activty with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment. Schroeder P, Lindemann C, Dettmar , Brieger J, Gosepath J, Pogorzelski B, Seimetz D, Atz J. Clin Transl Oncol. 2011 Dec;13(12):889-98. See abstract

First surgical experience of intraperitoneal treatment with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) for epithelial ovarian cancer. Papanikolaou G, Fotopoulou C, Braicu I, Chekerov R, Schmidt SC, Pietzner K, Sehouli J. Anticancer Res. 2011 Aug;31(8):2603-8. See abstract

Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Baumann K, Pfisterer J, Wimberger P, Burchardi N, Kurzeder C, du Bois A, Loibl S, Sehouli J, Huober J, Schmalfeldt B, Vergote I, Lück HJ, Wagner U. Gynecol Oncol. 2011 Oct;123(1):27-32. See absract

Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites.Ott MG, Marmé F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, Essing MM, Linke R, Seimetz D. Int J Cancer. 2011 Jun 23. doi:10.1002/ijc.26258. See abstract

Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, muticenter, phase I/II trial. Ströhlein MA, Lordick F, Rüttinger D, Grützner KU Schemanski OC, Jäger M, Lindhofer H, Hennig M, Jauch KW, Peschel C, Heiss MM. Onkologie. 2011;34(3):8-7. See abstract

Immunomonitoring Results of a Phase II/III Study in malignant ascites patients with the Trifunctional Antibody Catumaxomab (anti-EpCAM x anti-CD3). JägerM, SchoberthA, RufP, HessJ, HennigM, SchmalfeldtB, WimbergerP, StröhleinMA, TheissenB, HeissMM, LindhoferH, Cancer Res. 2012 Jan 1;72(1):24-32 See abstract

Fist patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report. Pietzner K, Jäger M, Schoberth A, Oskay-Özelik G, Kuhberg M, Lindhofer H, Sehouli J. Med Oncol, 2011 May 5. See abstract

Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab). Seimetz D. J Caner, 2011;2:309-16. See abstract

Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphoctic leukaemia depend on immune-mediated mechanism. Boehrer S, Schoeder P, Mueller T, Atz J, Chow KU. Anticancer Drugs.2011 Jul;22(6):519-30. See abstract

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients.Ruf P, Kluge M, Jäger M, Burges A, Volovat C, Heiss MM, Hess J, Wimberger P, Brandt B, Lindhofer H.
Br J Clin Pharmacol. 2010 Jun
See abstract

Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action. Hirschhaeuser F, Walenta S, Mueller-Klieser W. Cancer Immunol Immunother. 2010 Jul 21.
See abstract

Palliative treatment of malignant ascites: profile of catumaxomab. Ammouri L, Prommer EE. 2010 May 25;4:103-10.
See abstract

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL. Int J Cancer. 2010 Apr 27.
See abstract

Structural and functional characterization of the trifunctional antibody catumaxomab.
Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, Hess J, Wasiliu M, Lindhofer H. MAbs. 2010 May 16;2(3).
See abstract

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAMxanti-CD3) as a targeted cancer immunotherapy. Seimetz D, Lindhofer H, Bokemeyer C. Cancer Treat Rev. 2010 Mar 26.
See abstract

Catumaxomab: Clinical development and future directions.Linke R, Klein A, Seimetz D. MAbs. 2010 Mar 16;2(2).
See abstract

Test system for trifunctional antibodies in 3D MCTS culture. Hirschhaeuser F, Leidig T, Rodday B, Lindemann C, Mueller-Klieser W. J Biomol Screen. 2009 Sep;14(8):980-90. Epub 2009 Aug 12.
See abstract

Current and future options in the treatment of malignant ascites in ovarian cancer.
Woopen H, Sehouli J. Anticancer Res. 2009 Aug;29(8):3353-9.
See abstract

Intraperitoneal immunotherapy to prevent peritoneal carcinomatosis in patients with advanced gastrointestinal malignancies. Ströhlein MA, Heiss MM. J Surg Oncol. 2009 Sep 15;100(4):329-30.
See abstract

Catumaxomab: A bispecific trifunctional antibody. Sebastian M, Kuemmel A, Schmidt M, Schmittel A. Drugs Today (Barc). 2009 Aug;45(8):589-97.
See abstract

Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer. Wimberger P, Heubner M, Lindhofer H, Jäger M, Kimmig R, Kasimir-Bauer S. Anticancer Res. 2009 May;29(5):1787-91.
See abstract

The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H. Cancer Res. 2009 May 15;69(10):4270-6. Epub 2009 May 12.
See abstract

Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study. Sebastian M et al.,
J Immunother. 2009 Feb-Mar;32(2):195-202.
See abstract

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Ströhlein MA, Siegel R, Jäger M, Lindhofer H, Jauch KW, Heiss MM. J Exp Clin Cancer Res. 2009 Feb 14;28:18.
See abstract

The evolving role of catumaxomab in gastric cancer. Lordick F. et al., Expert Opin Biol Ther. 2008 Sep;8(9):1407-15.
See abstract

Ertumaxomab: a trifunctional antibody for breast cancer treatment. Philipp Kiewe & Eckhard Thiel, Expert Opin Investig Drugs. 2008 Oct;17(10):1553-8.
See abstract

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion. Buhmann et al., Bone Marrow Transplant. 2008 Oct 13.
See abstract

Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Stanglmaier et al., Int J Cancer. 2008 Sep 1;123(5):1181-9.
See abstract

Intraoperative immunotherapy with the trifunctional antibody catumaxomab in patients with advanced gastric, colon, and pancreatic cancer: A pilot phase I study. Stroehlein M. et al., 2008 Gastrointestinal Cancers Symposium
See abstract

Treatment of epithelial cancer patients with malignant ascites using catumaxomab: Results of the non-ovarian stratum of a phase II/ III study. Parsons S. L. et al., 2008 Gastrointestinal Cancers Symposium
See abstract

Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study. Sebastian M, Passlick B, Friccius-Quecke H, Jäger M, Lindhofer H, Kanniess F, Wiewrodt R, Thiel E, Buhl R, Schmittel A. Cancer Immunol Immunother. 2007 Oct;56(10):1637-44. Epub 2007 Apr 5.
See abstract

Effects of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) on proliferation and cytokine secretion of immune cells in malignant pleural effusion. Sebastian M. et al., 2007 ASCO Annual Meeting
See abstract

Immunomonitoring results of a pivotal phase II/ III study with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in ovarian cancer patients with malignant ascites. Jaeger M. J. et al., 2007 ASCO Annual Meeting
See abstract

Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: Results of a phase II/ III study. Parsons S. L. et al., 2007 ASCO Annual Meeting
See abstract

Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients. Belau A. et al., 2007 ASCO Annual Meeting
See abstract

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Ruf P. et al., Br J Cancer. 2007 Aug 6;97(3):315-21. Epub 2007 Jul 10.
See abstract

Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM x Anti-CD3 Antibody: A Phase I/II Study. Burges A. et al., Clin Cancer Res. 2007 July 1;13, 3899-3905
See abstract
 
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Kiewe P. et al., Clin Cancer Res. 2006 May 15;12(10):3085-91
See abstract
 
Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: A matched-pair analysis. Stroehlein M. A. et al., 2006 ASCO Annual Meeting
See abstract

Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3): Results of a phase I/II study. Sebastian M. et al., 2006 ASCO Annual Meeting
See abstract
 
Treatment of non-small cell lung cancer (NSCLC) patients with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3): Results of a phase I/II study. Passlick B. et al., 2006 ASCO Annual Meeting
See abstract

Use of trifunctional bispecific antibodies to prevent graft-versus-host disease induced by allogeneic lymphocytes. Morecki S. et al., Blood. 2006 Feb 15;107(4):1564-9
See abstract

Lasting remission following multimodal treatment in a patient with metastatic breast cancer. Stemmler H. J. et al., Anticancer Drugs. 2005 Nov;16(10):1135-1137.
See abstract

Prednisolone reduces TNF-alpha release by PBMCs activated with a trifunctional bispecific antibody but not their anti-tumor activity. Walz A. et al., Anticancer Res. 2005 Nov-Dec;25(6B):4239-43.
See abstract

Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study. Stemmler H. J. et al., Anticancer Res. 2005 Jul-Aug;25(4):3047-54.
See abstract

Immunotherapy of malignant ascites with trifunctional antibodies. Heiss, M. M. et al., Int J Cancer. 2005 Nov 10;117(3):435-43.
See abstract

Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Kiewe P. et al., 2005 ASCO Annual Meeting
See abstract

Treatment of peritoneal carcinomatosis due to GI-tract cancer by intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpcAM x anti-CD3): Results of a phase I/II trial. Stroehlein M. A. et al., 2005 ASCO Annual Meeting
See abstract

Immunotherapy with the trifunctional antibody removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: Results of a phase I/II study. Jaeger M. et al., 2004 ASCO Annual Meeting
See abstract

Intraperitoneal immunotherapy of peritoneal carcinomatosis from solid tumors by trifunctional antibodies. Stroehlein M. et al., 2004 ASCO Annual Meeting
See abstract

Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Schmitt M. et al., Int J Oncol. 2004 Oct;25(4):841-8.
See abstract
 
Two new trifunctional antibodies for the therapy of human malignant melanoma. Ruf P. et al., Int J Cancer. 2004 Feb 20;108(5):725-32.
See abstract
 
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Ruf P. et al., Blood. 2001 Oct 15;98(8): 2526-34.
See abstract
 
Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). Riesenberg R. et al., J Histochem Cytochem. 2001 Jul;49(7):911-7.
See abstract
 
TNFalpha contributes to the antitumor activity of a bispecific, trifunctional antibody. Zeidler R. et al., Anticancer Res. 2001 Sep-Oct;21(5):3499-503.
See abstract
 
The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Zeidler R. et al., Br J Cancer. 2000 Jul;83(2):261-6.
See abstract
 
Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. Zeidler R. et al., J Immunol. 1999 Aug 1;163(3): 1246-52
See abstract
 
Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. Lindhofer H. et al., J Immunol. 1995 Jul 1;155(1):219-25.
See abstract